Close Menu

SAN FRANCISCO (GenomeWeb News) - Thermo Fisher Scientific intends to increase its R&D spending in 2010 and expand its operating footprint in a handful of low-cost regions around the world.

Speaking today to investors at the JP Morgan Healthcare Conference held here, Thermo President and CEO Marc Casper said that the firm expects its R&D investments to target three key areas: mass spectrometry, specialty diagnostics, and bioscience reagents. However, he did not provide an estimate for the planned increased investment.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.

Oct
23
Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.